/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

ERASCA INC.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$3.36 0.1384(13.84%) ERAS at 04 Dec 2025 04:30 PM Biotechnology
Lowest Today 2.93
Highest Today 3.37
Today’s Open 2.94
Prev. Close 2.89
52 Week High 3.38
52 Week Low 1.01
Day’s Range: Low 2.93 High 3.37
52-Week Range: Low 1.01 High 3.38
1 day return -
1 Week return +3.61
1 month return +42.02
3 month return +122.63
6 month return +114.65
1 year return +5.44
3 year return -54.73
5 year return -
10 year return -

Institutional Holdings

T. Rowe Price Investment Management,Inc. 7.17

VR Adviser, LLC 6.30

BlackRock Inc 5.35

Logos Global Management LP 5.29

Suvretta Capital Management, LLC 5.11

Vanguard Group Inc 4.48

Paradigm Biocapital Advisors LP 4.20

ARCH VENTURE CORP 3.90

Siren, L.L.C. 3.09

Vanguard Total Stock Mkt Idx Inv 2.58

Vivo Capital, LLC 2.38

T. Rowe Price Small-Cap Value 2.09

5AM Venture Management, LLC 1.91

Geode Capital Management, LLC 1.70

iShares Russell 2000 ETF 1.49

Affinity Asset Advisors, LLC 1.44

State Street Corp 1.41

T. Rowe Price U.S. SC Value Eq Tr-D 1.39

Millennium Management LLC 1.34

T. Rowe Price US Small-Cap Core Equity 1.26

T. Rowe Price Small-Cap Stock 1.26

SILVERARC CAPITAL MANAGEMENT, LLC 0.91

Vanguard Institutional Extnd Mkt Idx Tr 0.81

Soleus Capital Management, L.P. 0.76

Marshall Wace Asset Management Ltd 0.73

Woodline Partners LP 0.73

T. Rowe Price Instl Small-Cap Stock 0.65

T. Rowe Price U.S. SC Core Eq Tr-D 0.64

Goldman Sachs Group Inc 0.64

Fidelity Small Cap Index 0.62

T. Rowe Price US Smlr Coms Eq A 0.56

iShares Russell 2000 Value ETF 0.55

Fidelity Extended Market Index 0.41

Schwab US Small-Cap ETF™ 0.35

iShares Biotechnology ETF 0.34

Vanguard Russell 2000 ETF 0.29

JPMorgan Small Cap Value I 0.28

State St Russell Sm Cap® Indx SL Cl I 0.23

Vanguard Health Care ETF 0.19

Schwab Small Cap Index 0.15

Market Status

Strong Buy: 5

Buy: 3

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 819.93 M

PB Ratio 2.5852

PE Ratio 0.0

Enterprise Value 659.26 M

Total Assets 502.53 M

Volume 5035637

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-230591000 -230.6M, FY22:-238160000 -238.2M, FY21:-150090000 -150.1M, FY20:-173069000 -173.1M, FY19:-10737000 -10.7M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-787000 -0.8M, Q1/2025:-822000 -0.8M, Q3/2024:null 0.0M, Q2/2024:-1100000 -1.1M

Quarterly Net worth Q3/2025:-30612000 -30.6M, Q2/2025:-33876000 -33.9M, Q1/2025:-30966000 -31.0M, Q3/2024:-31200000 -31.2M, Q2/2024:-63201000 -63.2M

Fund house & investment objective

Company Information Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-altered solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGRF and RAS/MAPK solid tumors. In addition, the company's products under development include ERAS-801, a central nervous system (CNS)-penetrant EGFR inhibitor for patients with EGFR-altered recurrent glioblastoma (GBM) which is in phase 1 clinical trials; and ERAS-007, an oral inhibitor of ERK1/2 and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It has a license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Organisation Biotechnology

Employees 103

Industry Biotechnology

CEO Dr. Jonathan E. Lim M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow